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The Shock-Filled Debate Continues*Michael J. Ackerman, MD, PHD,yzx Christopher V. DeSimone, MD, PHDySEE PAGE 879P atients with Brugada syndrome (BrS) havebeneﬁted greatly from the work of the Bru-gada brothers, and guideline-based manage-
ment was ﬁrst generated at conferences in 2002 and
2005 to provide recommendations for best practices
(1,2). These documents include the basis for the
management of asymptomatic patients, especially
with respect to risk stratiﬁcation, recommendations
for electrophysiologic study (EPS) and ventricular
arrhythmia (VA) provocation, and criteria for im-
plantable cardioverter-deﬁbrillator (ICD) placement
(1,2). A consensus was reached that EPS should be
performed in asymptomatic patients with family his-
tories of Brugada-associated sudden cardiac death
(SCD), but ﬁrm recommendations for asymptomatic
patients with negative family histories were lacking
(1). ICD therapy was recommended for patients with
asymptomatic BrS who satisﬁed the triad of: 1) a
spontaneous or drug-induced type 1 Brugada electro-
cardiographic (ECG) pattern; 2) a family history of
SCD secondary to BrS; and 3) demonstrable induc-
ibility of VA on EPS (2).*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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the contents of this paper to disclose.Eight years after the second consensus document,
the 2013 international guidelines gave a class IIb
indication for ICD implantation in patients found to
have sustained VA inducibility on EPS (3). These most
recent guidelines provide a soft-hearted recommen-
dation to “consider” ICD implantation in a patient
with inducibility of VA (3), but realistically, this might
as well be equated with inducible VA on EPS ¼ ICD,
especially given that we are dealing with life-and-
death considerations. However, the report also pro-
vides a more stoic statement that ICD therapy does
not have a role in asymptomatic patients, but it again
becomes gentler with respect to asymptomatic pa-
tients by recommending that they should be risk
stratiﬁed; one of these factors is VA inducibility on
EPS (3). At ﬁrst pass, a clinician may wonder why
these guideline and consensus recommendations
have been issued with a lack of gusto.In this issue of the Journal, Conte et al. (4) from the
Brugada group in Belgium report their 20-year,
single-center experience of ICD use in patients with
BrS. They describe ﬁndings from a cohort of 176 pa-
tients with both ICDs and ECG ﬁndings of either drug-
induced or spontaneous type 1 Brugada pattern. This
is a male-predominant cohort (67%), with a mean age
of 43 years (range: 2 to 77 years) and a mean follow-up
period of almost 7 years. The importance of ICD
therapy in this study is reﬂected by the number of
patients with VAs (17%), electrical storm (2.3%), or
death (7.5%). Multivariate analysis showed that both
aborted cardiac arrest and VA inducibility on EPS
were independent predictors of appropriate ICD
shock delivery. However, these ﬁndings must be
examined in the context of delivery of inappropriate
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890(18.7%) and appropriate (15.9%) shocks, as well as the
large number of device-related complications (15.9%).
The investigators conclude that ICD therapy can be
associated with a sizable amount of appropriate shock
therapy in patients with BrS, and EPS may be useful
to identify patients with asymptomatic BrS who may
beneﬁt from ICD placement.
Does this study provide the information needed for
the proverbial “slam-dunk” recommendation when
facing a patient with asymptomatic BrS? Namely, EPS
should be performed, and if VA is induced, an ICD
should be implanted. It seems as though the “World
Cup of Electrophysiology” has been going on much
longer then the recent tournament in Brazil, as
“match play” for this discussion ﬁrst began in 2002
with conﬂicting reports (5,6). The Brugada group re-
ported that 33% of patients who were asymptomatic
(with a spontaneous or drug-induced type 1 Brugada
ECG pattern) had an 8% incidence of ventricular
ﬁbrillation or SCD at a mean follow-up of 2 years (5).
Notably, they used only 1 site of ventricular stimula-
tion (the right ventricular apex) and used 3 extra-
stimulations down to a cycle length of 200 ms (5). In
the same year, the Priori group (6) reported con-
trasting ﬁndings regarding the natural history of
patients with BrS, ﬁnding poor sensitivity and speci-
ﬁcity in predicting ventricular ﬁbrillation from EPS
inducibility.
In 2003, the Brugada group published another
study supporting the utility of EPS in risk stratiﬁca-
tion, reporting a 6-fold increased risk for those with
inducible VAs, as well as better prediction perfor-
mance of the test in the asymptomatic population (7).
In 2005, Eckardt et al. (8) reported on a cohort in
which 59% of patients had spontaneous type 1 Bru-
gada ECG pattern, and only 1 of these asymptomatic
patients had an event (in the setting of an additional
year of follow-up when compared with the Brugada
cohort). Even more disconcerting was that in the 9
patients who went on to have events, 4 did not have
inducible VAs; this was despite the use of 2 sites for
stimulation and 3 premature beats. The investigators
proposed that the Brugada cohort was composed of
patients with a much higher risk “substrate,” because
the Eckardt and Priori cohorts had a much lower rate
of family history of SCD (8).
It was just past “halftime” in 2010, when the
FINGER (France, Italy, the Netherlands, and Germany)
Brugada Syndrome Registry was reported (9). Al-
though a statistically signiﬁcant percent of symp-
tomatic (46%) compared with asymptomatic patients
(37%) were inducible on EPS, SCD occurred in only
0.4% of patients without ICD implantation (9). In
2012, the Priori group (10) published the PRELUDE(Programmed Electrical Stimulation Predictive Value)
study, which provided the strongest evidence against
the use of EPS in asymptomatic patients. In that
study, even though inducibility of 40% was found on
EPS, 9 events still occurred among the total 14 pa-
tients who were “noninducible.” A few elegant as-
pects of the study further denounced the utility of
EPS: 1) 2 sites were used for stimulation, the right
ventricular apex and outﬂow tract; 2) stricter pro-
tocols were used, with only single or double stimula-
tions, but still showing a poorer correlation of
outcomes and inducibility; and 3) poor reliability and
reproducibility of EPS were demonstrated (only 34%
of studies were reproducible) (10).
Not only has EPS been shown to be unreliable in
some cohorts, but how can we explain the issue of the
large number of false positives and false negatives to
justify ICD placement to our patients? If these are the
guidelines, then we must be prepared to accept the
fact of inappropriate shocks and device complica-
tions. The investigators of the present study rightly
discuss the issues of ICDs in this population
compared with patients without BrS receiving ICD
therapy for structural heart disease: patients with BrS
live longer post device placement, and because of
younger age and more activity, they have a greater
propensity for lead fractures, require multiple
generator exchanges over a lifetime, and experience
quality-of-life issues from inappropriate shocks (4).
In the follow-up period, 16% of patients had device-
related complications, and almost three-quarters of
these patients were younger than 40 years (4). We
must therefore take into account the additional risk
we are putting patients at over a longer follow-up
period; this can be on the order of decades. Further
appreciation can be deduced from the shock rate per
year (4). A simple extrapolation from the group with
syncope calculates a mean of 3 inappropriate shocks
every 5 years. In contrast, patients with aborted car-
diac arrest and asymptomatic patients would have
about 1 inappropriate shock every 5 years. In the
setting of a 40-year-old patient with BrS who lived
to the age of 80 years, ICD implantation would
confer a mean of 8 inappropriate shocks over the rest
of that patient’s lifetime. This may be quite a telling
number and situation to ponder when discussing ICD
implantation.
In light of such controversy and the lack of clarity,
there is a strain on the general acceptance of induc-
ibility of VA on EPS as the “make-or-break” step for
ICD implantation. The present study is unlikely to put
this controversy to rest but will likely lead to an
“overtime period” in this ongoing debate. At one end
of the ﬁeld, the last stand for EPS may be a study that
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891involves a standardized medication regimen, sched-
uling patients for EPS as the ﬁrst case of the day to
minimize variation in timing, and an agreement on
protocol delivery. At the other end of the ﬁeld lies the
charge toward other prognostic factors, such as ven-
tricular effective refractory period and QRS frag-
mentation (10).
Ultimately, it may be that the recommendations
cannot be completely generalizable and that the
Brugada cohort has an inherently different substrate
of BrS that we are unable to detect, or, to date, we are
simply unaware of the cellular and genetic milieu that
places these patients at higher risk. Until the best
strategy is developed and shown to be generalizableto all cohorts, discussion should continue, wherein
both the clinician and the patient are paired up as
decision makers. Protecting the goal of prevention
from ventricular ﬁbrillation, as well as quality-of-life
issues, should be jointly discussed, along with the
risks and beneﬁts of ICD implantation, such that we
present a fair and balanced view of the information as
it currently exists.
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